Insulin,dosage
3 ML insulin, regular, human 100 UNT/ML Pen Injector [Novolin R]
Dosage and administration
See Full Prescribing Information for important administration instructions.
Subcutaneous injection: inject subcutaneously 30 minutes before a meal into the abdominal area, buttocks, thigh or the upper arm. Rotate injection sites to reduce risk of lipodystrophy and localized cutaneous amyloidosis.
Intravenous use: administer intravenously ONLY under medical supervision at concentrations from 0.05 unit/mL to 1 unit/mL in infusion systems using polypropylene infusion bags.
Individualize dose based on route of administration, metabolic needs, blood glucose monitoring results and glycemic control goal.
NOVOLIN R given by subcutaneous injection should generally be used in regimens with an intermediate- or long-acting insulin.
Can be mixed with NOVOLIN N.
2.1 Important
Administration Instructions Always check insulin labels before administration.
Inspect NOVOLIN R visually before use. It should appear clear and colorless. Do not use NOVOLIN R if particulate matter or coloration is seen.
Use of NOVOLIN R in insulin pumps is not recommended because of the risk of precipitation.
2.2 Route of
Administration Subcutaneous Administration
Inject NOVOLIN R subcutaneously approximately 30 minutes prior to the start of a meal into the abdominal area, buttocks, thigh, or the upper arm.
Rotate injection sites within the same region from one injection to the next to reduce the risk of lipodystrophy and localized cutaneous amyloidosis. Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis. Intravenous Administration
Administer NOVOLIN R intravenously ONLY under medical supervision with close monitoring of blood glucose and potassium levels to reduce the risk of hypoglycemia and hypokalemia.
Dilute NOVOLIN R to concentrations from 0.05 unit/mL to 1 unit/mL insulin in infusion systems using polypropylene infusion bags. NOVOLIN R is stable in infusion fluids such as 0.9% sodium chloride, 5% dextrose, or 10% dextrose with 40 mmol/L potassium chloride. Intravenous infusion bags are stable at room temperature for 24 hours.
2.3 Dosage Information •
Individualize and adjust the dosage of NOVOLIN R based on route of administration, the individual's metabolic needs, blood glucose monitoring results and glycemic control goal.
NOVOLIN R given by subcutaneous injection should generally be used in regimens that include an intermediate or long-acting insulin.
During changes to a patient’s insulin regimen, increase the frequency of blood glucose monitoring.
Dosage adjustments may be needed with changes in physical activity, changes in meal patterns (i.e., macronutrient content or timing of food intake), changes in renal or hepatic function or during acute illness.
Dosage adjustment may be needed when switching from another insulin to NOVOLIN R.
2.4 Dosage Adjustment due to
Drug Interactions
Dosage adjustment may be needed when NOVOLIN R is co-administered with certain drugs.
2.5 Instructions for
Mixing with Other Insulins for Subcutaneous Injection
NOVOLIN R can be mixed with NOVOLIN N.
When mixing, the NOVOLIN R should be drawn into the syringe first and the mixture should be injected immediately after mixing.
Text above is quoted in full from the FDA-approved drug label published by openFDA, effective November 23, 2022. Matched to this product by RxNorm code. Cross-references to other sections of the full prescribing information have been removed, since they point to a document not shown here. Nothing else is changed: no sentence is shortened, reworded or summarised.
This page reproduces regulatory text for reference. It is not medical advice, and KenyRx is not a pharmacy or a prescriber. Talk to a doctor or pharmacist about whether a medicine is right for you.
See what it costs — price without insurance